2025-10-26 10:07Financial Performance - Total revenue for the third quarter of 2025 reached RMB 12,057,434,626.40, representing a year-on-year increase of 15.26%[12] - The total profit for the period was RMB 5,129,651,792.47, showing a significant increase of 82.89% compared to the same quarter last year[12] - Net profit attributable to shareholders was RMB 3,514,630,329.36, reflecting a growth of 53.27% year-on-year[12] - The basic earnings per share for the quarter was RMB 1.24, an increase of 55.00% compared to the same period last year[12] - The company reported a net profit attributable to shareholders of RMB 3.25 billion, a 53.27% increase compared to the previous period[17] - The total profit increased by 82.89% year-on-year, driven by a focus on enhancing CRDMO business operations[17] - Net profit for Q3 2025 was RMB 3,547,837 thousand, a 39.2% increase from RMB 2,549,030 thousand in Q3 2024[52] - The net profit attributable to the parent company for the first three quarters of 2025 was RMB 11,801.9 million, a significant increase of 81% from RMB 6,532.9 million in the same period of 2024[63] Revenue Growth - The company achieved operating revenue of RMB 32.86 billion for the first three quarters of 2025, representing an 18.6% year-on-year growth[23] - Continuous operating business revenue grew by 22.5% year-on-year, with chemical business revenue reaching RMB 25.98 billion, up 29.3%[23] - Revenue for Q3 2025 reached RMB 12,044,962 thousand, a 19.7% increase from RMB 10,063,435 thousand in Q3 2024[51] - Total revenue for the first three quarters of 2025 was RMB 32,450,065 thousand, a 22.4% increase from RMB 26,487,694 thousand in the same period of 2024[54] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 94,606,135,416.07, up 17.78% from the previous year[13] - Total liabilities as of September 30, 2025, were RMB 23,133.6 million, compared to RMB 21,240.2 million at the end of 2024, showing an increase of 9%[58] - Current assets totaled ¥53.81 billion as of September 30, 2025, compared to ¥38.69 billion at the end of 2024, representing a 39.0% growth[37] - The total current assets increased to RMB 53,812.3 million as of September 30, 2025, compared to RMB 38,690.2 million at the end of 2024, reflecting a growth of 39%[58] Cash Flow - The company reported a net cash flow from operating activities of RMB 11,412,834,667.47, which increased by 36.21% compared to the previous year[12] - Cash flow from operating activities generated ¥11.41 billion, compared to ¥8.38 billion in the same period last year, marking a 36.3% increase[46] - The company’s investment activities generated a net cash inflow of RMB 946.4 million in the first three quarters of 2025, a turnaround from a net outflow of RMB 2,866.6 million in the same period of 2024[61] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥825.65 million, down from ¥954.04 million in the same period of 2024, indicating a 13.5% decrease[40] - Research and development expenses for Q3 2025 were RMB 311,732 thousand, slightly down from RMB 302,434 thousand in Q3 2024[51] Business Operations - The company continues to enhance its CRDMO business model to improve research and development efficiency for clients[10] - The company has enabled 75 products to be approved for market in the SMO business, with a cumulative total of 331 products over the past decade[24] - The company has developed a one-stop compound identification software that improves identification efficiency by 83% for nucleic acid and peptide metabolites[24] Market Position and Future Outlook - The company expects 2025 operating revenue to return to double-digit growth, with an adjusted growth rate of 17-18% and total revenue forecasted between RMB 43.5 billion and RMB 44 billion[25] - The company maintains a leading position in the Asia-Pacific industry for drug safety evaluation and continues to support clients in global licensing cooperation[24]